• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gsk Plc ADR (NY: GSK )

    40.91 +0.05 (+0.12%)
    Official Closing Price Updated: 7:00 PM EDT, Apr 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,461,980
    Open 41.06
    Bid (Size) 40.42 (1)
    Ask (Size) 41.32 (1)
    Prev. Close 40.86
    Today's Range 40.80 - 41.11
    52wk Range 33.33 - 43.84
    Shares Outstanding 5,385,189,617
    Dividend Yield 3.53%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    What's Going On With Pfizer Stock On Thursday?
    GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S. 
    Via Benzinga
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
    Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory... 
    Via Benzinga
    Topics Brexit
    Exposures Brexit

    Performance

    YTD
    +9.06%
    +9.06%
    1 Month
    -4.39%
    -4.39%
    3 Month
    +5.33%
    +5.33%
    6 Month
    +14.66%
    +14.66%
    1 Year
    +13.86%
    +13.86%

    More News

    Read More
    Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future
    Via Benzinga
    GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years
    Via Benzinga
    Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
    Via Benzinga
    Peering Into GSK's Recent Short Interest
    Via Benzinga
    Down 75%. Is Agenus Stock a Buy on the Dip?
    Via The Motley Fool
    CureVac, GS Partner Release Data On Influenza Vaccine Study
    Via Benzinga
    In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
    Via MarketBeat
    Exposures Product Safety
    2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
    Via The Motley Fool
    Russell 2000 Index Best And Worst Performing Stocks Of 2024
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
    Via Investor's Business Daily
    Exposures Product Safety
    Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
    Via The Motley Fool
    Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
    Via Benzinga
    GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial Cancer
    Via Benzinga
    Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B
    Via Benzinga
    Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
    From GSK plc
    Via Business Wire
    Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
    Via InvestorPlace
    Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
    Via InvestorPlace
    Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
    Via Benzinga
    3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
    Via InvestorPlace
    GSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study
    Via Benzinga
    GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
    From GSK plc
    Via Business Wire
    Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.